This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
by Zacks Equity Research
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -14.29% and 2.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -44.44% and 9.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its second-quarter earnings release, given the absence of a marketed product.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.
Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.
Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 9.30% and 3.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) closed at $7.47 in the latest trading session, marking a -1.32% move from the prior day.
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 13.04% and 11.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
13F Season: 3 Whales to Follow
by Andrew Rocco
Tracking 13F filings is crucial for market participants seeking to understand trends, identify potential investment opportunities, and monitor the transactions of Wall Street's most influential investors. Stock Strategist Andrew Rocco breaks down the 3 most important filings this 13F season.
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.